TOKYO -- Daiichi Sankyo, a Japanese drugmaker that has not had a blockbuster product for nearly a decade, is surging in market value, joining the 5 trillion yen ($46 billion) club that also includes such marquee names as Nintendo and Honda Motor.
Pharmaceuticals
Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold
Market cap doubles on surprise breakthrough by a specialist in lifestyle diseases
.jpg?width=780&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto)
Daiichi Sankyo's expertise in chemical synthesis played a key role in the development of a promising cancer drug. © Reuters
Read Next
Latest on Pharmaceuticals
